Published in Lupus on January 01, 1999
Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2011) 0.98
C1q complement component and -antibodies reflect SLE activity and kidney involvement. Clin Rheumatol (2005) 0.97
The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin Rheumatol (2006) 0.94
Differences in regional brain activation patterns assessed by functional magnetic resonance imaging in patients with systemic lupus erythematosus stratified by disease duration. Mol Med (2011) 0.90
IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis (2005) 0.89
Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients. Am J Med Sci (2012) 0.86
Rheumatic disease among Oklahoma tribal populations: a cross-sectional study. J Rheumatol (2012) 0.85
Development and initial validation of a self-assessed lupus organ damage instrument. Arthritis Care Res (Hoboken) (2010) 0.85
Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J (2002) 0.80
Pentraxin 3 Plasma Levels and Disease Activity in Systemic Lupus Erythematosus. Autoimmune Dis (2015) 0.78
Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations. Sci Rep (2016) 0.76
Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease. Arthritis Res Ther (2017) 0.75
Discriminating infectious meningitis versus neuropsychiatric involvement in patients with systemic lupus erythematosus: a single-center experience. Clin Rheumatol (2014) 0.75
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum (1992) 14.73
The bimodal mortality pattern of systemic lupus erythematosus. Am J Med (1976) 3.47
Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum (1988) 2.62
Accelerated nodulosis, pleural effusion, and pericardial tamponade during methotrexate therapy. J Rheumatol (1994) 2.62
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.49
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med (1977) 2.09
Methotrexate in systemic lupus erythematosus. J Rheumatol (1994) 2.08
Vitamin D insufficiency in a large female SLE cohort. Lupus (2009) 2.02
Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum (1992) 1.88
Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus (2000) 1.59
Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol (2000) 1.57
The systemic effects of intra-articular corticosteroid. J Rheumatol (1974) 1.57
Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol (2001) 1.56
Venous syndromes and pulmonary embolism in systemic lupus erythematosus. Ann Rheum Dis (1980) 1.52
Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol (1995) 1.52
The use of single photon emission computerized tomography in neuropsychiatric SLE: a pilot study. J Rheumatol (1995) 1.43
Morbidity in systemic lupus erythematosus. J Rheumatol Suppl (1987) 1.41
Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J Rheumatol (1994) 1.35
Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol (1992) 1.34
The lupus activity criteria count (LACC). J Rheumatol (1984) 1.34
The nature and outcome of infection in systemic lupus erythematosus. Lupus (2002) 1.34
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum (2008) 1.34
Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol (2000) 1.31
Systemic lupus erythematosus in males. Medicine (Baltimore) (1983) 1.29
Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol (1995) 1.29
Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med (1985) 1.28
Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis (2007) 1.28
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2009) 1.27
Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol (1991) 1.27
Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme. J Rheumatol (1985) 1.27
Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus (2001) 1.26
Neuropsychiatric lupus. J Rheumatol (1980) 1.25
Felty's syndrome. Clinical and serological analysis of 34 cases. Ann Rheum Dis (1977) 1.24
Azathioprine in rheumatoid arthritis: a long-term follow-up study. Arthritis Rheum (1975) 1.22
Malignancy in systemic lupus erythematosus. Arthritis Rheum (1996) 1.19
Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares. J Rheumatol (1994) 1.17
Systemic lupus erythematosus with negative LE cells and antinuclear factor. J Rheumatol (1978) 1.16
Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med (1979) 1.15
Postdiarrheal arthropathy of Yersinia pseudotuberculosis. Can Med Assoc J (1978) 1.15
Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol (1999) 1.14
Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine. Arthritis Rheum (1977) 1.13
Serial renal biopsy in systemic lupus erythematosus. J Rheumatol (2000) 1.12
Azathioprine in rheumatoid arthritis. A double-blind, cross over study. Arthritis Rheum (1973) 1.12
Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J Rheumatol (2000) 1.12
Asymptomatic spondylodiscitis. An unusual feature of ankylosing spondylitis. Arthritis Rheum (1974) 1.11
Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol (1998) 1.09
Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am (2000) 1.08
The liver in systemic lupus erythematosus. Q J Med (1984) 1.05
SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus (2011) 1.05
Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. Arthritis Care Res (2000) 1.03
Fatigue in lupus is not correlated with disease activity. J Rheumatol (1998) 1.02
Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol (1999) 1.02
Long-term outcome in Felty's syndrome. Ann Rheum Dis (1982) 1.01
Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum (2008) 1.01
Prostaglandin E1 therapy for digital ulcers in scleroderma. Can Med Assoc J (1982) 1.00
KIRs and autoimmune disease: studies in systemic lupus erythematosus and scleroderma. Tissue Antigens (2007) 0.99
CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum (1995) 0.99
Malignancy in progressive systemic sclerosis--association with breast carcinoma. J Rheumatol (1983) 0.99
Late mortality in SLE--"the price we pay for control". J Rheumatol (1980) 0.99
Pulmonary hypertension in systemic lupus. Lupus (2004) 0.99
Spinal entheseal new bone formation: the early changes of spinal diffuse idiopathic skeletal hyperostosis. J Rheumatol (1983) 0.98
Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol (1998) 0.98
Acute leukemia in rheumatoid arthritis treated with cytotoxic agents. J Rheumatol (1976) 0.98
Systemic lupus erythematosus in a patient with C4 deficiency. J Rheumatol (1982) 0.98
Gold-induced enterocolitis. Case report and literature review. J Rheumatol (1976) 0.97
Selective deficiency of the fourth component of complement in a patient with systemic lupus erythematosus (SLE): immunochemical and biological studies. Clin Exp Immunol (1981) 0.97
The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol (1999) 0.96
Lost-to-follow-up study in systemic lupus erythematosus (SLE). Lupus (2000) 0.96
Dilemmas in neuropsychiatric lupus. Rheum Dis Clin North Am (1993) 0.96
Studies into the occurrence of soluble antigen-antibody complexes in disease. V. Second assessment of correlation between the rheumatoid biologically active factor (RBAF) and the clinical features of rheumatoid arthritis. Arthritis Rheum (1973) 0.93
Systemic lupus erythematosus and pregnancy. J Rheumatol (1981) 0.93
Hyperosmolar, non-ketotic diabetic coma. Can Med Assoc J (1968) 0.92
SLEDAI-2K for a 30-day window. Lupus (2009) 0.92
Cranial computerized tomography in systemic lupus erythematosus. J Rheumatol (1983) 0.91
Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity. J Rheumatol (1994) 0.91
"Latent lupus". J Rheumatol (1989) 0.90
Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum Dis (1999) 0.90
Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol (1991) 0.90
A family study of the antiphospholipid syndrome associated with other autoimmune diseases. J Rheumatol (1992) 0.89
Breast cancer in systemic lupus erythematosus. Oncology (2013) 0.89
Fibromyalgia is a major contributor to quality of life in lupus. J Rheumatol (1997) 0.89
Clinical predictors of fetal outcome in systemic lupus erythematosus. J Rheumatol (1998) 0.89
Peripheral enthesopathy in diffuse idiopathic skeletal hyperostosis (DISH): a radiologic study. J Rheumatol (1982) 0.89
Impairment of left ventricular diastolic function in systemic lupus erythematosus. Am J Cardiol (1992) 0.88
Systemic lupus erythematosus with paraproteinemia. Arthritis Rheum (1984) 0.88
Evolving spectrum of mortality and morbidity in SLE. Lupus (1999) 0.88
The significance of thrombocytopenia in systemic lupus erythematosus. Arthritis Rheum (1983) 0.87
Pattern of neuropsychologic dysfunction in inactive systemic lupus erythematosus. Neuropsychiatry Neuropsychol Behav Neurol (1997) 0.87
Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis (2011) 0.87
Radiographic features of the hand in diffuse idiopathic skeletal hyperostosis (DISH): comparison with normal subjects and acromegalic patients. Radiology (1981) 0.87
Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J Rheumatol (2000) 0.87
Mixed leukocyte reaction (MLR) in rheumatoid arthritis: dose-response kinetics. Clin Immunol Immunopathol (1976) 0.87
Peripheral vascular disease in patients with systemic lupus erythematosus. Ann Rheum Dis (1992) 0.87
Nail lesions in systemic lupus erythematosus. J Rheumatol (1978) 0.86
Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol (2001) 0.86
A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). Lupus (1996) 0.85
Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy. J Rheumatol (1999) 0.85